Flucinar N, ointment 15 g

Flucinard N is a combined drug with anti-inflammatory and antibacterial action.

Fluocinolone acetonide is a synthetic GCS for external use. It is 40 times more active than hydrocortisone. It has anti-inflammatory, antipruritic, antiexudative, anti-allergic and vasoconstrictor action. The mechanism of anti-inflammatory action is not fully elucidated. It is thought that fluocinolone acetonide decreases manifestations of the inflammatory process by inhibiting the synthesis of prostaglandins and leukotrienes through inhibition of phospholipase A2 activity and reducing the release of arachidonic acid from cell membrane phospholipids. As a result, hyperemia and exudation in the lesion are reduced. Stabilizes cellular and subcellular (including lysosomal) membranes. Reduces output of proteolytic enzymes from lysosomes. Reduces membrane permeability, mitotic activity and release of inflammatory mediators.

On skin exposure prevents marginal accumulation of neutrophils, which leads to a decrease in inflammatory exudate and lymphokine production, inhibition of macrophage migration, reduction of infiltration and granulation processes. Inhibits the alteration phase and limits the focus of inflammation, reduces the migration of leukocytes and lymphocytes to the focus of inflammation. Inhibits the synthesis or release of cytokines (interleukins and interferon) from lymphocytes and macrophages. Reduces the severity of the early immune response.

Neomycin is an antibiotic of aminoglycoside group. In low concentrations it has bacteriostatic action, in high concentrations it is bactericidal. Mechanism of action is related to direct effect on ribosomes and inhibition of protein synthesis in bacterial cell.

Flucinar N is active against Gram-positive micro-negroms: Staphylococcus spp., Streptococcus spp., Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus antracis, Clostridium spp., Actinomyces spp, Neisseria meningitidis; Gram-negative micro-organisms: Escherichia coli, Shigella spp., Salmonella spp., Proteus spp., Enterobacter aerogenes, Vibrio cholerae, Haemophilus influenzae, Klebsiella pneumoniae, Bordetella pertussis, Pasteurella multocida, Borrelia spp., Treponema pallidum, Fusobacterium spp., Leptospira spp.

It has activity against acid-resistant Mycobacterium tuberculosis.

Microbial resistance to neomycin develops slowly and to a small extent.

As a result of the combined action of fluocinolone acetonide and neomycin, the drug suppresses the development of inflammatory-allergic skin reactions complicated by bacterial infection.

Indications

Allergic dermatoses complicated by bacterial infection caused by neomycin-sensitive flora:

allergic (including contact, occupational, solar) dermatitis;
eczema (including contact, constitutional, coin-shaped, seborrheic);
hives;
psoriasis (including scalp);
erythema multiforme;
erythroderma;
atopic dermatitis;
pruritus;
dermatoses that cannot be treated with other corticosteroids (including lichen planus, lupus erythematosus /skin manifestations/);
secondary infections from insect bites.

Bacterial skin infections caused by neomycin-sensitive flora, complicated by the development of allergic reactions:

impetigo;
infected diaper rash.

First degree burns.

Pharmacological effect

Flucinar N is a combination drug with anti-inflammatory and antibacterial effects.

Fluocinolone acetonide is a synthetic corticosteroid for external use. It is 40 times more active than hydrocortisone. It has anti-inflammatory, antipruritic, antiexudative, antiallergic and vasoconstrictive effects. The mechanism of anti-inflammatory action is not fully understood. It is believed that fluocinolone acetonide reduces the manifestations of the inflammatory process by inhibiting the synthesis of prostaglandins and leukotrienes by inhibiting the activity of phospholipase A2 and reducing the release of arachidonic acid from cell membrane phospholipids. As a result, hyperemia and exudation in the lesion are reduced. Stabilizes cellular and subcellular (including lysosomal) membranes. Reduces the release of proteolytic enzymes from lysosomes. Reduces membrane permeability, mitotic activity and the release of inflammatory mediators.

When exposed to the skin, the marginal accumulation of neutrophils is prevented, which leads to a decrease in inflammatory exudate and the production of lymphokines, inhibition of macrophage migration, and a decrease in the processes of infiltration and granulation. Inhibits the alteration phase and limits the focus of inflammation, reduces the migration of leukocytes and lymphocytes to the focus of inflammation. Inhibits the synthesis or release of cytokines (interleukins and interferon) from lymphocytes and macrophages. Reduces the severity of the early immune response.

Neomycin is an antibiotic of the aminoglycoside group. In low concentrations it has a bacteriostatic effect, in high concentrations it has a bactericidal effect. The mechanism of action is associated with a direct effect on ribosomes and inhibition of protein synthesis in the bacterial cell.

Flucinar N is active against gram-positive microorganisms: Staphylococcus spp., Streptococcus spp., Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium spp., Actinomyces spp., Neisseria meningitidis; gram-negative microorganisms: Escherichia coli, Shigella spp., Salmonella spp., Proteus spp., Enterobacter aerogenes, Vibrio cholerae, Haemophilus influenzae, Klebsiella pneumoniae, Bordetella pertussis, Pasteurella multocida, Borrelia spp., Treponema pallidum, Fusobacterium spp., Leptospira spp.

Has activity against acid-fast Mycobacterium tuberculosis.

Resistance of microorganisms to neomycin develops slowly and to a small extent.

As a result of the combined effect of fluocinolone acetonide and neomycin, the drug suppresses the development of inflammatory and allergic skin reactions complicated by bacterial infection.

Special instructions

With long-term use and when applied to large areas of skin (under occlusive dressings), patients should undergo systematic examinations (systemic side effects may occur).

Active ingredient

Neomycin, Fluocinolone acetonide

Composition

Active ingredients:

fluocinolone acetonide 0.25 mg,

neomycin sulfate 5 mg,

excipients:

propylene glycol;

liquid paraffin;

lanolin anhydrous;

Vaseline white

Contraindications

Hypersensitivity;
acne;
bacterial (including tuberculosis),
fungal, viral and tumor diseases of the skin.

Side Effects

Atrophy of the skin and subcutaneous fat,
lupus-like syndrome with a mild course,
the appearance or exacerbation of symptoms of lichen planus,
epithelialization disorders,
slower healing of wounds and ulcerative lesions,
petechiae,
steroid purpura,
striae,
hirsutism,
baldness in women,
maculopapular skin rash.

Overdose

Symptoms: if the dosage regimen is not followed (long-term use of the drug over large areas of the skin), systemic side effects of the drug may develop, such as increased blood pressure, edema, and immunosuppressive effects.

Treatment: drug withdrawal.

Storage conditions

In a place protected from light, at a temperature not exceeding 25°C.

Shelf life

3 years.

Manufacturer

Pharmaceutical plant Elfa A.O., Poland